研究单位：[1]Beijing Tongren Hospital,Beijing,China,100730[2]Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.[3]Oyster Point Pharma, Inc.[4]The Second Hospital of Anhui Medical University,Hefei,Anhui,China[5]Beijing Hospital,Beijing,China[6]Peking University Third Hospital,Beijing,China[7]Zhujiang Hospital of Southern Medical University,Guangzhou,Guangdong,China[8]Tianjin Medical University Eye Hospital,Tianjin,China[9]The Second Affiliated Hospital Zhejiang University School of Medicine,Hangzhou,Zhejiang,China[10]The Affiliated Hospital of Guizhou Medical University,Guiyang,Guizhou,China[11]Shijiazhuang People's Hospital,Shijiazhuang,Hebei,China[12]Hebei Eye Hospital,Xingtai,Hebei,China[13]The First Affiliated Hospital of Harbin Medical University,Harbin,Heilongjiang,China[14]Henan Eye Hospital,Zhengzhou,Henan,China[15]Union Hospital Tongji Medical College Huazhong University of Science and Technology,Wuhan,Hubei,China[16]Wuhan Aier Eye Hospital Hankou Hospital,Wuhan,Hubei,China[17]Nanjing First Hospital,Nanjing,Jiangsu,China[18]The First Bethune Hospital of Jilin University,Changchun,Jilin,China[19]Eye Hospital of Shandong First Medical University,Jinan,Shandong,China[20]Weifang Eye Hospital,Weifang,Shandong,China[21]Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine,Shanghai,Shanghai,China[22]Tongji Hospital of Tongji University,Shanghai,Shanghai,China
The objective of this study is to evaluate the safety and effectiveness of OC-01 (varenicline solution) Nasal Spray as compared to placebo (vehicle) on signs and symptoms of dry eye disease.
